Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scandipharm (US) targets bronchitis market

This article was originally published in Clinica

Executive Summary

Scandipharm (US) has received US FDA clearance to market its Flutter mucus removal device for patients with chronic bronchitis and bronchiectasis. The hand-held device, which was cleared for use by cystic fibrosis sufferers last August (see Clinica No 617, p 19), effectively shakes mucus from the air passages through vibrations caused by a moving steel ball.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT091566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel